Smith HO - Search Results

1

Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, Prossnitz ER, Verschraegen CF. Arias-Pulido H, et al. Among authors: smith ho. Gynecol Oncol. 2009 Sep;114(3):480-5. doi: 10.1016/j.ygyno.2009.05.045. Epub 2009 Jun 27. Gynecol Oncol. 2009. PMID: 19560192 Free PMC article.

2

GPR30 predicts poor survival for ovarian cancer.

Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER. Smith HO, et al. Gynecol Oncol. 2009 Sep;114(3):465-71. doi: 10.1016/j.ygyno.2009.05.015. Epub 2009 Jun 6. Gynecol Oncol. 2009. PMID: 19501895 Free PMC article.

3

GPR30: a novel indicator of poor survival for endometrial carcinoma.

Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER. Smith HO, et al. Am J Obstet Gynecol. 2007 Apr;196(4):386.e1-9; discussion 386.e9-11. doi: 10.1016/j.ajog.2007.01.004. Am J Obstet Gynecol. 2007. PMID: 17403429

4

A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I. Fekrazad HM, et al. Among authors: smith ho. Am J Clin Oncol. 2010 Aug;33(4):393-7. doi: 10.1097/COC.0b013e3181b2043f. Am J Clin Oncol. 2010. PMID: 19884803 Clinical Trial.

5

Is there a difference in survival for IA1 and IA2 adenocarcinoma of the uterine cervix?

Smith HO, Qualls CR, Romero AA, Webb JC, Dorin MH, Padilla LA, Key CR. Smith HO, et al. Gynecol Oncol. 2002 May;85(2):229-41. doi: 10.1006/gyno.2002.6635. Gynecol Oncol. 2002. PMID: 11972381

6

Incidence and survival rates for female malignant germ cell tumors.

Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, Qualls CR. Smith HO, et al. Obstet Gynecol. 2006 May;107(5):1075-85. doi: 10.1097/01.AOG.0000216004.22588.ce. Obstet Gynecol. 2006. PMID: 16648414

7

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Prossnitz ER, et al. Among authors: smith ho. Annu Rev Physiol. 2008;70:165-90. doi: 10.1146/annurev.physiol.70.113006.100518. Annu Rev Physiol. 2008. PMID: 18271749 Review.

8

Absence of epidermal growth factor receptor mutations in cervical cancer.

Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF. Arias-Pulido H, et al. Among authors: smith ho. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54. doi: 10.1111/j.1525-1438.2007.01111.x. Epub 2007 Oct 19. Int J Gynecol Cancer. 2008. PMID: 17949425

9

The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Smith HO, Tiffany MF, Qualls CR, Key CR. Smith HO, et al. Gynecol Oncol. 2000 Aug;78(2):97-105. doi: 10.1006/gyno.2000.5826. Gynecol Oncol. 2000. PMID: 10926787

10

Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.

Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO. Huang GS, et al. Among authors: smith ho. Am J Obstet Gynecol. 2010 Sep;203(3):242.e1-5. doi: 10.1016/j.ajog.2010.04.046. Epub 2010 Jun 3. Am J Obstet Gynecol. 2010. PMID: 20605134 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters